Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure.

Fiche publication

Date publication

mai 2020

Journal

European journal of heart failure

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick

Tous les auteurs :
Rossignol P, Williams B, Mayo MR, Warren S, Arthur S, Ackourey G, White WB, Agarwal R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32452085

Résumé

The AMBER trial demonstrated that concomitant use of patiromer enabled the more persistent use of spironolactone by reducing the risk of hyperkalaemia in patients with resistant hypertension and advanced chronic kidney disease. We report herein the pre-specified subgroup analysis in patients with heart failure (HF).